Anne Marion Pearson

Bryony Pearson,A. Pearson

DOI: https://doi.org/10.1136/bmj.i4401

2016-08-12

British Medical Journal

Abstract:Anne Marion Pearson (nee Macgregor) completed her preregistration year at the Royal Free Hospital and then Scarborough Hospital, before leaving the UK for four years with her husband to provide primary medical care for the British Phosphate Commission on Nauru …

What problem does this paper attempt to address?

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Jin Zhang,Shenhe Jin,Xiaojun Guo,W. Qian

DOI: https://doi.org/10.1177/0300060518799612

2018-01-01

Journal of International Medical Research

Abstract:The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma.
CD47 as a promising therapeutic target in oncology

Hai Zhao,Shuangshuang Song,Junwei Ma,Zhiyong Yan,Hongwei Xie,Ying Feng,Shuseng Che

DOI: https://doi.org/10.3389/fimmu.2022.757480

IF: 7.3

2022-08-22

Frontiers in Immunology

Abstract:CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.

immunology
Is CD47 an Innate Immune Checkpoint for Tumor Evasion?

Xiaojuan Liu,Hyunwoo Kwon,Zihai Li,Yang-xin Fu

DOI: https://doi.org/10.1186/s13045-016-0381-z

2017-01-01

Abstract:Cluster of differentiation 47 (CD47) (also known as integrin-associated protein) is a ubiquitously expressed glycoprotein of the immunoglobulin superfamily that plays a critical role in self-recognition. Various solid and hematologic cancers exploit CD47 expression in order to evade immunological eradication, and its overexpression is clinically correlated with poor prognoses. One essential mechanism behind CD47-mediated immune evasion is that it can interact with signal regulatory protein-alpha (SIRPα) expressed on myeloid cells, causing phosphorylation of the SIRPα cytoplasmic immunoreceptor tyrosine-based inhibition motifs and recruitment of Src homology 2 domain-containing tyrosine phosphatases to ultimately result in delivering an anti-phagocytic-"don't eat me"-signal. Given its essential role as a negative checkpoint for innate immunity and subsequent adaptive immunity, CD47-SIRPα axis has been explored as a new target for cancer immunotherapy and its disruption has demonstrated great therapeutic promise. Indeed, CD47 blocking antibodies have been found to decrease primary tumor size and/or metastasis in various pre-clinical models. In this review, we highlight the various functions of CD47, discuss anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborate on the clinical potential of CD47 blockade. We argue that CD47 is a checkpoint molecule for both innate and adaptive immunity for tumor evasion and is thus a promising target for cancer immunotherapy.
Insights into CD47/SIRPα Axis-Targeting Tumor Immunotherapy

Xuyao Zhang,Jiajun Fan,Dianwen Ju

DOI: https://doi.org/10.1093/abt/tby006

2018-01-01

Antibody Therapeutics

Abstract:ABSTRACT During the last decade, inhibitors targeting immune checkpoint programmed death ligand 1/PD-1 and cytotoxic T-lymphocyte-associated protein 4 have been one of the most significant advances for cancer therapy in clinic. However, most of these therapies focused on stimulating the adaptive immune system-mediated elimination of tumor. Recent studies indicated that CD47/Signal-regulatory protein alpha (SIRPα), an innate anti-phagocytic axis between cancer cells and macrophages, could be a promising therapeutic target. Here, we review the current knowledge about developing CD47/SIRPα checkpoint inhibitors, avoiding potential side effect and designing optimal combination therapies, and highlight the key points for future clinical applications of CD47/SIRPα axis-targeted tumor immunotherapy.
The RTOG Outcomes Model: economic end points and measures

A. Konski,D. Watkins-Bruner

DOI: https://doi.org/10.1517/14656566.5.3.513

2004-03-01

Expert Opinion on Pharmacotherapy

Abstract:Recognising the value added by economic evaluations of clinical trials and the interaction of clinical, humanistic and economic end points, the Radiation Therapy Oncology Group (RTOG) has developed an Outcomes Model that guides the comprehensive assessment of this triad of end points. This paper will focus on the economic component of the model. The Economic Impact Committee was founded in 1994 to study the economic impact of clinical trials of cancer care. A steep learning curve ensued with considerable time initially spent understanding the methodology of economic analysis. Since then, economic analyses have been performed on RTOG clinical trials involving treatments for patients with non-small cell lung cancer, locally-advanced head and neck cancer and prostate cancer. As the care of cancer patients evolves with time, so has the economic analyses performed by the Economic Impact Committee. This paper documents the evolution of the cost-effectiveness analyses of RTOG from performing average cost-utility analysis to more technically sophisticated Monte Carlo simulation of Markov models, to incorporating prospective economic analyses as an initial end point. Briefly, results indicated that, accounting for quality-adjusted survival, concurrent chemotherapy and radiation for the treatment of non-small cell lung cancer, more aggressive radiation fractionation schedules for head and neck cancer and the addition of hormone therapy to radiation for prostate cancer are within the range of economically acceptable recommendations. The RTOG economic analyses have provided information that can further inform clinicians and policy makers of the value added of new or improved treatments.
Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.

Chenxuan Zhao,Jinhui Wu,Haojie Jiang,Yuchen Wang,Chao Wang,Yang Liu,Yiqiao Hu

DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00073

2022-04-18

Molecular Pharmaceutics

Abstract:Cancer is still a major disease that is currently difficult for humans to overcome. When the expression of the cluster of differentiation 47 (CD47) is upregulated, tumor cells interact with the macrophage inhibitory receptor signal regulatory protein α (SIRPα) to transmit the "Don't eat me" signal, thereby avoiding phagocytosis by the macrophages. Therefore, when the CD47-SIRPα axis is inhibited, the macrophages' phagocytic function can be restored and can also exert antitumor effects. This Review mainly introduces recent advances in tumor therapy targeted on the CD47-SIRPα axis, including the antibody and fusion protein, small molecule, gene therapy, cell therapy, and drug delivery system, to inhibit the function of CD47 expressed on tumor cells and promote tumor phagocytosis by macrophages. In addition, this Review also summarizes the current approaches to avoid anemia, a common side effect of CD47-SIRPα inhibitions, and provides ideas for clinical transformation.

Medicine
Blocking CD47 with Restructured Peptide Nanoparticles for Motivating Phagocytosis to Inhibit Tumor Progression

Yiyi Xia,Tiantian Wang,Linjie Wu,Haiqing Zhong,Yi Zhou,Peng Ke,Xiaoyan Bao,Qi Dai,Qiyao Yang,Yiying Lu,Donghang Xu,Min Liang,Min Han

DOI: https://doi.org/10.1039/d2bm00189f

2022-01-01

Biomaterials Science

Abstract:Phagocytosis checkpoints, especially targeting CD47, have shown encouraging therapeutic effects. However, there are currently many shortcomings and challenges with immune checkpoint blockades (ICBs). Inspired by the phenomenon of molecular self-assembly, we modify the CD47 targeting peptide (4N1K) onto the self-assembled peptide FY4, as well as the concatenation of PEG at the other terminal via the AZO group to construct hypoxia-responsive nanoparticles (PEG-AZO-FY4-4N1K, PAP NPs), utilizing the peptide as a part of the anti-tumor therapy machine. After degradation, PAP NPs can self-assemble to form fibrous networks and anchor CD47 on the surface of tumor cells, promoting their recognition and phagocytosis by macrophages and relieving immune escape. Self-assembled peptides can interweave on the surface of tumor cells, fully exploiting their morphological advantages to impede normal cell interaction and metastasis. The PAP NPs work synergistically with Doxorubicin (DOX) to further maximize the efficacy of chemoimmunotherapy. In conclusion, this strategy pioneers the progress of self-assembled peptides in biomedicine and promises a novel breakthrough in the development of checkpoint inhibitor therapies.
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy

Zihao Li,Yue Li,Jing Gao,Yilin Fu,Peiyan Hua,Yingying Jing,Mingjun Cai,Hongda Wang,Ti Tong

DOI: https://doi.org/10.1016/j.lfs.2021.119150

IF: 6.78

2021-05-01

Life Sciences

Abstract:<p>As a transmembrane protein, CD47 plays an important role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, inhibition of NO signal transduction and other related reactions. Upon the interaction of innate immune checkpoint CD47-SIRPα occurrence, they send a "don't eat me" signal to the macrophages. This signal ultimately helps tumors achieve immune escape by inhibiting macrophage contraction to prevent tumor cells from phagocytosis. Therefore, the importance of CD47-SIRPα immune checkpoint inhibitors in tumor immunotherapy has attracted more attention in recent years. Based on the cognitive improvement of the effect with CD47 in tumor microenvironment and tumor characteristics, the pace of tumor treatment strategies for CD47-SIRPα immune checkpoint inhibitors has gradually accelerated. In this review, we introduced the high expression of CD47 in cancer cells to avoid phagocytosis by immune cells and the importance of CD47 in the structure of cancer microenvironment and the maintenance of cancer cell characteristics. Given the role of the innate immune system in tumorigenesis and development, an improved understanding of the anti-tumor process of innate immune checkpoint inhibitors can lay the foundation for more effective combinations with other anti-tumor treatment strategies.</p>

pharmacology & pharmacy,medicine, research & experimental
Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Can Chen,Runlu Wang,Xi Chen,Yulong Hou,Jingting Jiang

DOI: https://doi.org/10.3389/fonc.2022.924740

IF: 4.7

2022-07-04

Frontiers in Oncology

Abstract:Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer.

oncology
Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Fan Wu,Hongyuan Pang,Fan Li,Mengqing Hua,Chuanwang Song,Jie Tang

DOI: https://doi.org/10.3892/ol.2024.14389

2024-04-10

Oncology Letters

Abstract:Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin‐1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma. Upregulation of CD47 expression facilitates the growth of numerous types of tumor cells, while downregulation of its expression promotes phagocytosis of tumor cells by macrophages, thereby limiting tumor growth. In addition, blocking CD47 activates the cyclic GMP‐AMP (cGAMP) synthase/cGAMP/interferon gene stimulating factor signaling pathway and initiates an adaptive immune response that kills tumor cells. The present review describes the structure, function and interactions of CD47 with its ligands, as well as its regulation of phagocytosis and tumor cell fate. It summarizes the therapeutics, mechanisms of action, research advances and challenges of targeting CD47. In addition, this paper provides an overview of the latest therapeutic options for targeting CD47, such as chimeric antigen receptor (CAR) T‐cells, CAR macrophages and nanotechnology‐based delivery systems, which are essential for future clinical research on targeting CD47.

oncology
Recent Advances of Tumor Therapy Based on the CD47-SIRP? Axis

Yuchen Wang,Chenxuan Zhao,Yang Liu,Chao Wang,Haojie Jiang,Yiqiao Hu,Jinhui Wu

DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00073

2022-01-01

Molecular Pharmaceutics

Abstract:Cancer is still a major disease that is currently difficult for humans to overcome. When the expression of thecluster of differentiation 47 (CD47) is upregulated, tumor cellsinteract with the macrophage inhibitory receptor signal regulatoryprotein alpha(SIRP alpha) to transmit the"Don't eat me"signal, therebyavoiding phagocytosis by the macrophages. Therefore, when theCD47-SIRP alpha axis is inhibited, the macrophages'phagocyticfunction can be restored and can also exert antitumor effects.This Review mainly introduces recent advances in tumor therapytargeted on the CD47-SIRP alpha axis, including the antibody andfusion protein, small molecule, gene therapy, cell therapy, and drug delivery system, to inhibit the function of CD47 expressed ontumor cells and promote tumor phagocytosis by macrophages. In addition, this Review also summarizes the current approaches toavoid anemia, a common side effect of CD47-SIRP alpha inhibitions, and provides ideas for clinical transformation
CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Zhenghai Tang,Ming-Chao Zhong,Jin Qian,Cristian Camilo Galindo,Dominique Davidson,Jiaxin Li,Yunlong Zhao,Enfu Hui,André Veillette

DOI: https://doi.org/10.1038/s41590-023-01671-2

IF: 30.5

2023-01-01

Nature Immunology

Abstract:Cancer cells often overexpress CD47, which triggers the inhibitory receptor SIRPα expressed on macrophages, to elude phagocytosis and antitumor immunity. Pharmacological blockade of CD47 or SIRPα is showing promise as anticancer therapy, although CD47 blockade has been associated with hematological toxicities that may reflect its broad expression pattern on normal cells. Here we found that, in addition to triggering SIRPα, CD47 suppressed phagocytosis by a SIRPα-independent mechanism. This mechanism prevented phagocytosis initiated by the pro-phagocytic ligand, SLAMF7, on tumor cells, due to a cis interaction between CD47 and SLAMF7. The CD47–SLAMF7 interaction was disrupted by CD47 blockade and by a first-in-class agonist SLAMF7 antibody, but not by SIRPα blockade, thereby promoting antitumor immunity. Hence, CD47 suppresses phagocytosis not only by engaging SIRPα, but also by masking cell-intrinsic pro-phagocytic ligands on tumor cells and knowledge of this mechanism may influence the decision between CD47 blockade or SIRPα blockade for therapeutic purposes.
CD47/SIRPα pathway mediates cancer immune escape and immunotherapy

Xiao Jia,Bingjun Yan,Xiaoqing Tian,Qian Liu,Jianhua Jin,Juanjuan Shi,Yongzhong Hou

DOI: https://doi.org/10.7150/ijbs.60782

2021-01-01

International Journal of Biological Sciences

Abstract:The adaptive immune checkpoints such as PD-1(programmed death-1)/PD-L1 (programmed death-ligand 1) play an important role in cancer immunotherapy, whereas increasing evidence suggests that cancer cell evades immune surveillance by innate immune checkpoints such as SIRPα (signal-regulatory protein α)/CD47 (cluster of differentiation 47). In multiple types of cancer cells and solid tumor tissues, highly expressed CD47 protein level has been observed, which is triggered by some transcription factors including NFκB, Myc, and HIF. As a transmembrane protein, the binding of CD47 to SIRPα ligand on phagocytes results in phagocytosis resistance and cancer cell immune escape. In contrast, CD47-SIRPα interaction blockade enhances cancer cell clearance by phagocytes such as macrophages and dendritic cells (DCs) to activate an innate immune response, whereas this process could promote antigen cross-presentation by antigen present cells (APCs) leading to T cell priming, consequently, activates an adaptive antitumor immune response. In this review, we discussed the current SIRPα-CD47 axis-mediated cancer cell immune escape and immunotherapy, which could provide an effective antitumor strategy by the innate and adaptive immune response.

biochemistry & molecular biology
Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Yilan Xu,Panruo Jiang,Zhenyan Xu,Haige Ye

DOI: https://doi.org/10.3389/fimmu.2024.1348852

IF: 7.3

2024-02-24

Frontiers in Immunology

Abstract:CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.

immunology
The landscape overview of CD47-based immunotherapy for hematological malignancies

Hua Yang,Yang Xun,Hua You

DOI: https://doi.org/10.1186/s40364-023-00456-x

2023-02-01

Biomarker Research

Abstract:Abstract Extensive clinical and experimental evidence suggests that macrophages play a crucial role in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy and malignant cells, regulates macrophage-mediated phagocytosis by sending a "don't eat me" signal to the signal regulatory protein alpha (SIRPα) receptor. Increasing evidence demonstrates that blocking CD47 interaction with SIRPα can enhance cancer cell clearance by macrophages. Additionally, inhibition of CD47/SIRPα interaction can increase antigen cross-presentation, leading to T-cell priming and an activated adaptive antitumor immune response. Therefore, inhibiting CD47/SIRPα axis has a significant impact on tumor immunotherapy. Studies on CD47 monoclonal antibodies are at the forefront of research, and impressive results have been obtained. Nevertheless, hematotoxicity, especially anemia, has become the most common adverse effect of the CD47 monoclonal antibody. More specific targeted drugs ( i.e. , bispecific antibodies, SIRPα/Fc fusion protein antibodies, and small-molecule inhibitors) have been developed to reduce hematotoxicity. Here, we review the present usage of CD47 antagonists for the treatment of lymphomas and hematologic neoplasms from the perspectives of structure, function, and clinical trials, including a comprehensive overview of the drugs in development.

oncology,medicine, research & experimental
Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

Shu Lian,Xiaodong Xie,Yusheng Lu,Lee Jia,Jia Lee

DOI: https://doi.org/10.2147/OTT.S220196

IF: 4

2019-11-04

OncoTargets and Therapy

Abstract:Shu Lian, 1 Xiaodong Xie, 1 Yusheng Lu, 1, 2, * Lee Jia 1, 2, * 1 Cancer Metastasis Alert and Prevention Center, College of Chemistry, Fuzhou University, Fuzhou, People's Republic of China; 2 Marine Drug R&D Center, Institute of Oceanography, Minjiang University, Fuzhou, 350108, People's Republic of China *These authors contributed equally to this work Correspondence: Lee Jia Cancer Metastasis Alert and Prevention Center, Fuzhou University, Sunlight Building, 6FL; Science Park, Xueyuan Road, University Town, Fuzhou 350116, Fujian, People's Republic of China Tel +86 591-22867183 Email cmapcjia1234@163.com Yusheng Lu Marine Drug R&D Center, Institute of Oceanography, Minjiang University, Xiyuangong Road, University Town, Fuzhou 350108, Fujian, People's Republic of China Tel +86-591-83760743 Email lu_yu_sheng@126.com The success of cancer immunotherapy on recognition checkpoints for killing cancer cells has raised a great interest of scientists in understanding new and old methods of immunotherapeutic. CD47 (cluster of differentiation 47) is a cell surface glycoprotein and widely expressed on cells, which belongs to the immunoglobulin (Ig) superfamily as a cell membrane receptor which serves in immune therapy. CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-α, also named CD172a or SHPS-1) which may escape from immune cells such as macrophage and T cells. Meanwhile, tumor cells express high CD47 protein which may secrete exosomes with high CD47 expression. The high CD47 expression-exosomes could serve the tumor metastasis process and provide transfer convenience for tumors on the microenvironment. CD47 on cancer cells can also affect the migration and invasion of cells. The high CD47 expression on tumor or CTC (circulating tumor cell) surface means the stronger migration and invasion and makes them escape from immune cells for phagocytosis such as T cells, NK (natural killer) cells and macrophage, which could be used for diagnosis and prognosis on cancer patients. Meanwhile, targeting CD47 combined with other biomarkers such as EpCAM (epithelial cell adhesion molecule), CD44, etc on cancer surface could be used to isolate CTCs from patients' blood. In terms of treatment, anti-CD47 antibody combined with another antibody such as anti-PD-L1 (programmed death-ligand 1) antibody or drugs such as rituximab, DOX or oxaliplatin also has better therapeutic effects and antitumor function to tumors. Using nanomaterials as an intermediary for CD47-related immune therapy could greatly increase the therapeutic effect and overcome multiple biological barriers for anti-CD47 antibody in vivo. In this review, we discuss the important role and the function of CD47 in tumor metastasis and also provide a reference for related research. Keywords: CD47, immune therapy, biological target, immune checkpoint

oncology,biotechnology & applied microbiology
[Studies on the metabolism and distribution of peroral or parenteral administered vitamin B12 in the organism].

B. Jasiński,G. Stiefel,H. Frei,F. Wuhrmann

DOI: https://doi.org/10.1016/0009-8981(56)90034-1

1956-03-01

Abstract:
The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer

Shelby N. Bess Matthew J. Igoe Timothy J. Muldoon Department of Biomedical Engineering,University of Arkansas,Fayetteville,Arkansas,USA

DOI: https://doi.org/10.1080/08820139.2024.2415409

2024-10-18

Immunological Investigations

Abstract:Background Immunotherapy is an emerging strategy in cancer therapeutics aimed at modulating the immune system to inhibit pro-tumor pathways and increase a tumor's sensitivity to chemotherapy. Several clinically approved immunotherapy treatments, such as monoclonal antibody treatments, have been successful in solid tumors such as breast, colorectal, and pancreatic. However, an outstanding challenge of these strategies is tumor cell resistance. One target of interest for immune cell modulation is targeting macrophages that enter the tumor microenvironment. More specifically, an immune checkpoint of interest is CD47. CD47 is a transmembrane protein that inhibits phagocytic activity by acting as a "don't eat me" signal. In both mice and humans, healthy cells can express CD47, while solid malignancies like colorectal and breast cancer express it most strongly.

immunology
Role of CD47 in tumor immunity: a potential target for combination therapy

Jing Huang,Fangkun Liu,Chenglong Li,Xisong Liang,Chuntao Li,Yuanyuan Liu,Zhenjie Yi,Liyang Zhang,Siqi Fu,Yu Zeng

DOI: https://doi.org/10.1038/s41598-022-13764-3

IF: 4.6

2022-06-15

Scientific Reports

Abstract:CD47 performs a vital function in cancer therapy by binding to different SIRPα, thrombospondin 1, and integrin. However, its role in tumor immunity and its correlation with prognosis among many cancer types remain unknown. The raw mRNA expression data of CD47 in cancer patients was downloaded from TCGA and GTEx datasets. The protein expression of CD47 was detected using a microarray. Kaplan Meier analysis and forest plot were performed to compare the effects of high and low expression of CD47 on overall survival in different cancers. In addition, the correlations between CD47 expression and immune cell infiltration, stromal components, immune checkpoint genes, tumor mutational burden (TMB), and microsatellite instability (MSI) were analyzed from the public database. The gene function was determined by Gene Set Enrichment Analysis (GSEA). The expressions of CD47 in CHOL, COAD, ESCA, HNSC, KIRC, STAD, and THCA were higher compared with normal tissues. Elevated expression of CD47 predicted poor prognosis in ACC, KICH, KIRP, LGG, PAAD and UCEC. CD47 expression was strongly associated with immune infiltrating cells among KICH, KIRP, LGG, and PAAD. In addition, significant positive correlations with most immune checkpoint genes including PDCD 1 (PD-1), CD274 (PD-L1), CTLA4 in BLCA, DLBC, KICH, KIRC, LUAD, LUSC, PAAD, PCPG, SKCM, STAD, UCEC, and UVM was noted for the expression of CD47. GSEA analysis demonstrated that CD47 was a key regulator in metabolism-related pathways. These findings provide novel evidence that CD47 could be utilized as a promising prognostic biomarker and combination treatment target in various cancers.

multidisciplinary sciences
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Haiqin Liao,Chengcheng Niu

DOI: https://doi.org/10.3389/fbioe.2022.887463

2022-04-26

Abstract:Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches.

Anne Marion Pearson

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

CD47 as a promising therapeutic target in oncology

Is CD47 an Innate Immune Checkpoint for Tumor Evasion?

Insights into CD47/SIRPα Axis-Targeting Tumor Immunotherapy

The RTOG Outcomes Model: economic end points and measures

Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.

Blocking CD47 with Restructured Peptide Nanoparticles for Motivating Phagocytosis to Inhibit Tumor Progression

The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy

Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Recent Advances of Tumor Therapy Based on the CD47-SIRP? Axis

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

The landscape overview of CD47-based immunotherapy for hematological malignancies

Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

[Studies on the metabolism and distribution of peroral or parenteral administered vitamin B12 in the organism].

The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer

Role of CD47 in tumor immunity: a potential target for combination therapy

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment